State Street’s Elicio Therapeutics ELTX Stock Holding History

State Street’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$541K	Buy	50,620 +4,320	+9%	+$41.7K	﹤0.01%	3637
2025 Q4	$369K	Buy	46,300 +8,000	+21%	+$72.6K	﹤0.01%	3758
2025 Q3	$419K	Buy	38,300 +16,700	+77%	+$169K	﹤0.01%	3699
2025 Q2	$167K	Hold	21,600	–	–	﹤0.01%	3880
2025 Q1	$133K	Sell	21,600 -300	-1%	-$2.32K	﹤0.01%	3910
2024 Q4	$107K	Hold	21,900	–	–	﹤0.01%	3973
2024 Q3	$110K	Hold	21,900	–	–	﹤0.01%	3960
2024 Q2	$90K	Buy	21,900 +4,300	+24%	+$36.4K	﹤0.01%	4035
2024 Q1	$134K	Buy	+17,600	New	+$88.2K	﹤0.01%	3969
2023 Q2	–	Sell	-1,270	Closed	-$7.37K	–	4690
2023 Q1	$7.37K	Hold	1,270	–	–	﹤0.01%	4757
2022 Q4	$10.3K	Hold	1,270	–	–	﹤0.01%	4804
2022 Q3	$12K	Sell	1,270 -300	-19%	-$3.13K	﹤0.01%	4882
2022 Q2	$18K	Sell	1,570 -18,979	-92%	-$303K	﹤0.01%	4883
2022 Q1	$436K	Sell	20,549 -2,122	-9%	-$47.9K	﹤0.01%	4110
2021 Q4	$657K	Buy	22,671 +6,684	+42%	+$338K	﹤0.01%	3918
2021 Q3	$1.56M	Buy	15,987 +7,446	+87%	+$804K	﹤0.01%	3679
2021 Q2	$1.11M	Buy	8,541 +3,840	+82%	+$554K	﹤0.01%	3645
2021 Q1	$849K	Buy	+4,701	New	+$907K	﹤0.01%	3658

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street's ELTX Position: Q1 2026 in Review

State Street increased its Elicio Therapeutics (ELTX) stake by 9.3% in Q1 2026, buying an estimated $41.7K and bringing the position to 50,620 shares worth $541K. The position accounts for ﹤0.01% of the portfolio, ranked #3637.

State Street first reported a position in ELTX in Q1 2021 and has held it in 18 quarters since. The position peaked at $1.56M in Q3 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

State Street held 50,620 shares of Elicio Therapeutics worth $541K as of Q1 2026.
State Street bought 4,320 Elicio Therapeutics shares in Q1 2026, an estimated $41.7K.
Elicio Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3637 holding.
State Street first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 18 quarters since.
State Street's Elicio Therapeutics position peaked at $1.56M in Q3 2021.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.